Terns Pharmaceuticals (TERN) Expected to Announce Earnings on Tuesday

Terns Pharmaceuticals (NASDAQ:TERN) will likely be issuing its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 30, 2026 at 4:00 PM ET.

Terns Pharmaceuticals Trading Up 2.4%

TERN stock opened at $49.61 on Tuesday. The firm’s 50-day moving average is $40.01 and its two-hundred day moving average is $28.10. The company has a market capitalization of $5.15 billion, a price-to-earnings ratio of -48.17 and a beta of -0.31. Terns Pharmaceuticals has a 52 week low of $1.87 and a 52 week high of $50.89.

Insider Activity at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, CEO Amy L. Burroughs sold 71,339 shares of Terns Pharmaceuticals stock in a transaction on Monday, January 5th. The stock was sold at an average price of $38.10, for a total value of $2,718,015.90. Following the completion of the transaction, the chief executive officer owned 138,976 shares in the company, valued at approximately $5,294,985.60. The trade was a 33.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Emil Kuriakose sold 1,155 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total value of $44,548.35. Following the completion of the transaction, the insider directly owned 50,365 shares in the company, valued at approximately $1,942,578.05. This represents a 2.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 170,409 shares of company stock worth $6,563,769 over the last three months. 1.50% of the stock is owned by company insiders.

Institutional Trading of Terns Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vestal Point Capital LP bought a new position in shares of Terns Pharmaceuticals in the fourth quarter valued at about $181,800,000. Janus Henderson Group PLC bought a new stake in Terns Pharmaceuticals during the 4th quarter worth about $136,496,000. Nearwater Capital Markets Ltd acquired a new stake in Terns Pharmaceuticals in the 4th quarter valued at about $68,874,000. Adage Capital Partners GP L.L.C. raised its stake in shares of Terns Pharmaceuticals by 40.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,550,000 shares of the company’s stock worth $224,220,000 after acquiring an additional 1,611,000 shares during the last quarter. Finally, Ikarian Capital LLC raised its stake in shares of Terns Pharmaceuticals by 872.2% in the fourth quarter. Ikarian Capital LLC now owns 1,596,378 shares of the company’s stock worth $64,494,000 after acquiring an additional 1,432,176 shares during the last quarter. 98.26% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently commented on TERN. Barclays raised their price objective on shares of Terns Pharmaceuticals from $36.00 to $56.00 and gave the company an “overweight” rating in a research note on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen cut Terns Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Citizens Jmp boosted their price objective on Terns Pharmaceuticals from $35.00 to $57.00 and gave the stock a “market outperform” rating in a research note on Thursday, December 11th. Finally, Leerink Partners began coverage on Terns Pharmaceuticals in a report on Monday, February 9th. They issued an “outperform” rating and a $58.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $58.11.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.